Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
Novartis axes a once 'first-in-class' prospect as another JAK program fails to clear a risk/benefit analysis
The JAK class can count one more clinical failure, the latest in a long string of setbacks that continues to cloud the future of these …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
